Clinical Pharmacokinetics

Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates
pp. 403-417(15)
Author: Buck M.L.

Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
pp. 419-436(18)
Authors: Gabizon A.; Shmeeda H.; Barenholz Y.

Clinical Pharmacokinetics of Antioxidants and Their Impact on Systemic Oxidative Stress
pp. 437-459(23)
Authors: Schwedhelm E.; Maas R.; Troost R.; Böger R.H.

Transdermal Drug Delivery of Insulin with Ultradeformable Carriers
pp. 461-474(14)
Author: Cevc G.

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers
pp. 475-484(10)
Authors: Johansson L.C.; Andersson M.; Fager G.; Gustafsson D.; Eriksson U.G.

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran
pp. 485-492(8)
Authors: Sarich T.C.; Teng R.; Peters G.R.; Wollbratt M.; Homolka R.; Svensson M.; Eriksson U.G.

Aminoglycoside Dosages and Nephrotoxicity: Quantitative Relationships
pp. 493-500(8)
Authors: Rougier F.; Ducher M.; Maurin M.; Corvaisier S.; Claude D.; Jelliffe R.; Maire P.